help button home button Endocrine Society JCEM ENDO 08
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hudson, P. L.
Right arrow Articles by MacLaughlin, D. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hudson, P. L.
Right arrow Articles by MacLaughlin, D. T.

Journal of Clinical Endocrinology & Metabolism, Vol 70, 16-22, Copyright © 1990 by Endocrine Society

ARTICLES

An immunoassay to detect human mullerian inhibiting substance in males and females during normal development

PL Hudson, I Dougas, PK Donahoe, RL Cate, J Epstein, RB Pepinsky and DT MacLaughlin
Pediatric Surgical Research Laboratory, Massachusetts General Hospital, Boston 02114.

An enzyme-linked immunosorbent assay has been developed to measure human Mullerian inhibiting substance (MIS) in biological fluids. The enzyme-linked immunosorbent assay is specific for MIS, with a sensitivity in human serum to 0.5 ng/ml and does not recognize transforming growth factor-beta 1 or -beta 2, LH, or FSH. It similarly fails to recognize other proteins secreted from the cell type into which the MIS gene was cloned. MIS was detected in the serum of normal newborns, infants, children, and adults. In males the serum level of MIS is 10-70 ng/mL at birth. The level increases slightly after birth, and then decreases to a basal level of 2-5 ng/mL after the first 10 yr of life. Newborn male urine contains minimal amounts of MIS (0.5 ng/mL). In females MIS is barely detectable in serum at birth, but rises to the basal level equal to that seen in males after 10 yr of age. Similar basal levels of MIS were found in adult ovarian follicular fluid. MIS levels were high in the serum of a female patient with a sex cord tumor (3200 ng/mL), but fell to 100 ng/mL after multiple excisional operations. In addition, a serum MIS level of 20 ng/mL was detected in a patient with an ovarian granulosa cell tumor. A sensitive assay for MIS could be useful in the diagnosis of patients with congenital abnormalities of sexual development and patients with Sertoli cell and/or other MIS-producing neoplasms. Other applications may also be recognized as the biology of MIS in both males and females is further elucidated.


This article has been cited by other articles:


Home page
 ReproductionHome page
E. W Kabithe and N. J Place
Photoperiod-dependent modulation of anti-Mullerian hormone in female Siberian hamsters, Phodopus sungorus
Reproduction, March 1, 2008; 135(3): 335 - 342.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
W. J.K. Hehenkamp, N. A. Volkers, F. J.M. Broekmans, F. H. de Jong, A. P.N. Themmen, E. Birnie, J. A. Reekers, and W. M. Ankum
Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy
Hum. Reprod., July 1, 2007; 22(7): 1996 - 2005.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
A. L. Marca and A. Volpe
The Anti-Mullerian hormone and ovarian cancer
Hum. Reprod. Update, May 1, 2007; 13(3): 265 - 273.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
D. B. Seifer, D. T. MacLaughlin, and H. S. Cuckle
Serum mullerian-inhibiting substance in Down's syndrome pregnancies
Hum. Reprod., April 1, 2007; 22(4): 1017 - 1020.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
A. La Marca, G. Stabile, A.C. Artenisio, and A. Volpe
Serum anti-Mullerian hormone throughout the human menstrual cycle
Hum. Reprod., December 1, 2006; 21(12): 3103 - 3107.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
T. T. Tran, D. L. Segev, V. Gupta, H. Kawakubo, G. Yeo, P. K. Donahoe, and S. Maheswaran
Mullerian Inhibiting Substance Regulates Androgen-Induced Gene Expression and Growth in Prostate Cancer Cells through a Nuclear Factor-{kappa}B-Dependent Smad-Independent Mechanism
Mol. Endocrinol., October 1, 2006; 20(10): 2382 - 2391.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
W. J. K. Hehenkamp, C. W. N. Looman, A. P. N. Themmen, F. H. de Jong, E. R. te Velde, and F. J. M. Broekmans
Anti-Mullerian Hormone Levels in the Spontaneous Menstrual Cycle Do Not Show Substantial Fluctuation
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 4057 - 4063.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
P. P. Szotek, R. Pieretti-Vanmarcke, P. T. Masiakos, D. M. Dinulescu, D. Connolly, R. Foster, D. Dombkowski, F. Preffer, D. T. MacLaughlin, and P. K. Donahoe
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness
PNAS, July 25, 2006; 103(30): 11154 - 11159.
[Abstract] [Full Text] [PDF]

Home page
 DevelopmentHome page
Y. Zhan, A. Fujino, D. T. MacLaughlin, T. F. Manganaro, P. P. Szotek, N. A. Arango, J. Teixeira, and P. K. Donahoe
Mullerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Mullerian duct regression
Development, June 15, 2006; 133(12): 2359 - 2369.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Pieretti-Vanmarcke, P. K. Donahoe, P. Szotek, T. Manganaro, M. K. Lorenzen, J. Lorenzen, D. C. Connolly, E. F. Halpern, and D. T. MacLaughlin
Recombinant Human Mullerian Inhibiting Substance Inhibits Long-term Growth of MIS Type II Receptor-Directed Transgenic Mouse Ovarian Cancers In vivo
Clin. Cancer Res., March 1, 2006; 12(5): 1593 - 1598.
[Abstract] [Full Text] [PDF]

Home page
 ReproductionHome page
J. A Visser, F. H de Jong, J. S E Laven, and A. P N Themmen
Anti-Mullerian hormone: a new marker for ovarian function
Reproduction, January 1, 2006; 131(1): 1 - 9.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
T. Silberstein, D.T. MacLaughlin, I. Shai, J.R. Trimarchi, G. Lambert-Messerlian, D.B. Seifer, D.L. Keefe, and A.S. Blazar
Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology
Hum. Reprod., January 1, 2006; 21(1): 159 - 163.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
T. Piltonen, L. Morin-Papunen, R. Koivunen, A. Perheentupa, A. Ruokonen, and J. S. Tapanainen
Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome
Hum. Reprod., July 1, 2005; 20(7): 1820 - 1826.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
A. La Marca, S. Giulini, R. Orvieto, V. De Leo, and A. Volpe
Anti-Mullerian hormone concentrations in maternal serum during pregnancy
Hum. Reprod., June 1, 2005; 20(6): 1569 - 1572.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
V. Gupta, J. L. Carey, H. Kawakubo, A. Muzikansky, J. E. Green, P. K. Donahoe, D. T. MacLaughlin, and S. Maheswaran
Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model
PNAS, March 1, 2005; 102(9): 3219 - 3224.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. J. Renaud, D. T. MacLaughlin, E. Oliva, B. R. Rueda, and P. K. Donahoe
Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance
PNAS, January 4, 2005; 102(1): 111 - 116.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
K. Lutchman Singh, M. Davies, and R. Chatterjee
Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing
Hum. Reprod. Update, January 1, 2005; 11(1): 69 - 89.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
A. La Marca, S. Malmusi, S. Giulini, L. F. Tamaro, R. Orvieto, P. Levratti, and A. Volpe
Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation
Hum. Reprod., December 1, 2004; 19(12): 2738 - 2741.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K. L. Britt, P. G. Stanton, M. Misso, E. R. Simpson, and J. K. Findlay
The Effects of Estrogen on the Expression of Genes Underlying the Differentiation of Somatic Cells in the Murine Gonad
Endocrinology, August 1, 2004; 145(8): 3950 - 3960.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
C. Belville, H. Van Vlijmen, C. Ehrenfels, B. Pepinsky, A. R. Rezaie, J.-Y. Picard, N. Josso, N. d. Clemente, and R. L. Cate
Mutations of the Anti-Mullerian Hormone Gene in Patients with Persistent Mullerian Duct Syndrome: Biosynthesis, Secretion, and Processing of the Abnormal Proteins and Analysis Using a Three-Dimensional Model
Mol. Endocrinol., March 1, 2004; 18(3): 708 - 721.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
A. Salva, M. P. Hardy, X.-f. Wu, C. M. Sottas, D. T. MacLaughlin, P. K. Donahoe, and M. M. Lee
Mullerian-Inhibiting Substance Inhibits Rat Leydig Cell Regeneration after Ethylene Dimethanesulphonate Ablation
Biol Reprod, March 1, 2004; 70(3): 600 - 607.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Misra, D. T. MacLaughlin, P. K. Donahoe, and M. M. Lee
The Role of Mullerian Inhibiting Substance in the Evaluation of Phenotypic Female Patients with Mild Degrees of Virilization
J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 787 - 792.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
R. Fanchin, L. M. Schonauer, C. Righini, J. Guibourdenche, R. Frydman, and J. Taieb
Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3
Hum. Reprod., February 1, 2003; 18(2): 323 - 327.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
R. Fanchin, L. M. Schonauer, C. Righini, N. Frydman, R. Frydman, and J. Taieb
Serum anti-Mullerian hormone dynamics during controlled ovarian hyperstimulation
Hum. Reprod., February 1, 2003; 18(2): 328 - 332.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Misra, D. T. MacLaughlin, P. K. Donahoe, and M. M. Lee
Measurement of Mullerian Inhibiting Substance Facilitates Management of Boys with Microphallus and Cryptorchidism
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3598 - 3602.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. E. Stephen, L. A. Pearsall, B. P. Christian, P. K. Donahoe, J. P. Vacanti, and D. T. MacLaughlin
Highly Purified Mullerian Inhibiting Substance Inhibits Human Ovarian Cancer in Vivo
Clin. Cancer Res., August 1, 2002; 8(8): 2640 - 2646.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. L. Segev, Y. Hoshiya, M. Hoshiya, T. T. Tran, J. L. Carey, A. E. Stephen, D. T. MacLaughlin, P. K. Donahoe, and S. Maheswaran
Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo
PNAS, January 1, 2002; (2002) 221599298.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. Teixeira, S. Maheswaran, and P. K. Donahoe
Mullerian Inhibiting Substance: An Instructive Developmental Hormone with Diagnostic and Possible Therapeutic Applications
Endocr. Rev., October 1, 2001; 22(5): 657 - 674.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. M. Trbovich, P. M. Sluss, V. M. Laurich, F. H. O'Neill, D. T. MacLaughlin, P. K. Donahoe, and J. Teixeira
Mullerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents
PNAS, March 1, 2001; (2001) 51632298.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. E. Stephen, P. T. Masiakos, D. L. Segev, J. P. Vacanti, P. K. Donahoe, and D. T. MacLaughlin
Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo
PNAS, February 22, 2001; (2001) 51625998.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
P. T. Masiakos, D. T. MacLaughlin, S. Maheswaran, J. Teixeira, A. F. Fuller Jr., P. C. Shah, D. J. Kehas, M. K. Kenneally, D. M. Dombkowski, T. U. Ha, et al.
Human Ovarian Cancer, Cell Lines, and Primary Ascites Cells Express the Human Mullerian Inhibiting Substance (MIS) Type II Receptor, Bind, and Are Responsive to MIS
Clin. Cancer Res., November 1, 1999; 5(11): 3488 - 3499.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. Rajpert-De Meyts, N. Jorgensen, N. Gram, J. Muller, R. L. Cate, and N. E. Skakkebak
Expression of Anti-Mullerian Hormone during Normal and Pathological Gonadal Development: Association with Differentiation of Sertoli and Granulosa Cells
J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3836 - 3844.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
J. Teixeira, E. Fynn-Thompson, A. H. Payne, and P. K. Donahoe
Mullerian-Inhibiting Substance Regulates Androgen Synthesis at the Transcriptional Level
Endocrinology, October 1, 1999; 140(10): 4732 - 4738.
[Abstract] [Full Text]

Home page
 EndocrinologyHome page
M. M. Lee, C. C. Seah, P. T. Masiakos, C. M. Sottas, F. I. Preffer, P. K. Donahoe, D. T. MacLaughlin, and M. P. Hardy
Mullerian-Inhibiting Substance Type II Receptor Expression and Function in Purified Rat Leydig Cells
Endocrinology, June 1, 1999; 140(6): 2819 - 2827.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. A. Rey, C. Belville, C. Nihoul-Fékété, L. Michel-Calemard, M. G. Forest, N. Lahlou, F. Jaubert, I. Mowszowicz, M. David, N. Saka, et al.
Evaluation of Gonadal Function in 107 Intersex Patients by Means of Serum Antimullerian Hormone Measurement
J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 627 - 631.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
W. Byrd, M. J. Bennett, B. R. Carr, Y. Dong, F. Wians, and W. Rainey
Regulation of Biologically Active Dimeric Inhibin A and B From Infancy to Adulthood in the Male
J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2849 - 2854.
[Abstract] [Full Text]

Home page
 Physiol. Rev.Home page
C. M. HAQQ and P. K. DONAHOE
Regulation of Sexual Dimorphism in Mammals
Physiol Rev, January 1, 1998; 78(1): 1 - 33.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. M. Lee, P. K. Donahoe, B. L. Silverman, T. Hasegawa, Y. Hasegawa, M. L. Gustafson, Y. Chang, and D. T. MacLaughlin
Measurements of Serum Mullerian Inhibiting Substance in the Evaluation of Children with Nonpalpable Gonads
N. Engl. J. Med., May 22, 1997; 336(21): 1480 - 1486.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. G. Forest
Serum Mullerian Inhibiting Substance Assay -- A New Diagnostic Test for Disorders of Gonadal Development
N. Engl. J. Med., May 22, 1997; 336(21): 1519 - 1521.
[Full Text]

Home page
 EndocrinologyHome page
E. A. Catlin, V. C. Tonnu, R. G. Ebb, B. A. Pacheco, T. F. Manganaro, R. M. Ezzell, P. K. Donahoe, and J. Teixeira
Mullerian Inhibiting Substance Inhibits Branching Morphogenesis and Induces Apoptosis in Fetal Rat Lung
Endocrinology, February 1, 1997; 138(2): 790 - 796.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. L. Segev, T. U. Ha, T. T. Tran, M. Kenneally, P. Harkin, M. Jung, D. T. MacLaughlin, P. K. Donahoe, and S. Maheswaran
Mullerian Inhibiting Substance Inhibits Breast Cancer Cell Growth through an NFkappa B-mediated Pathway
J. Biol. Chem., September 8, 2000; 275(37): 28371 - 28379.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. U. Ha, D. L. Segev, D. Barbie, P. T. Masiakos, T. T. Tran, D. Dombkowski, M. Glander, T. R. Clarke, H. K. Lorenzo, P. K. Donahoe, et al.
Mullerian Inhibiting Substance Inhibits Ovarian Cell Growth through an Rb-independent Mechanism
J. Biol. Chem., November 17, 2000; 275(47): 37101 - 37109.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. L. Segev, Y. Hoshiya, A. E. Stephen, M. Hoshiya, T. T. Tran, D. T. MacLaughlin, P. K. Donahoe, and S. Maheswaran
Mullerian Inhibiting Substance Regulates NFkappa B Signaling and Growth of Mammary Epithelial Cells in Vivo
J. Biol. Chem., July 13, 2001; 276(29): 26799 - 26806.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. E. Stephen, P. T. Masiakos, D. L. Segev, J. P. Vacanti, P. K. Donahoe, and D. T. MacLaughlin
Tissue-engineered cells producing complex recombinant proteins inhibit ovarian cancer in vivo
PNAS, March 13, 2001; 98(6): 3214 - 3219.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. M. Trbovich, P. M. Sluss, V. M. Laurich, F. H. O'Neill, D. T. MacLaughlin, P. K. Donahoe, and J. Teixeira
Mullerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents
PNAS, March 13, 2001; 98(6): 3393 - 3397.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. L. Segev, Y. Hoshiya, M. Hoshiya, T. T. Tran, J. L. Carey, A. E. Stephen, D. T. MacLaughlin, P. K. Donahoe, and S. Maheswaran
Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo
PNAS, January 8, 2002; 99(1): 239 - 244.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society